自身免疫性肝病移植等待名单患者的二十年比较分析
该研究利用1995年至2014年英国和美国国家移植登记数据,分析因原发性胆汁性胆管炎(PBC)、原发性硬化性胆管炎(PSC)或自身免疫性肝炎(AIH)等待肝移植的成人患者趋势。结果显示PBC等待名单人数在两国均下降50%,至2014年PSC成为自身免疫性肝病中肝移植的主要指征,且不同疾病和国家间在年龄、性别、疾病严重度评分和种族方面存在差异。
要点
- PBC等待名单人数在英国和美国均下降50%,女性与男性比例下降近50%。
- 至2014年,PSC成为两国自身免疫性肝病中肝移植的主要指征。
- PSC男性等待名单时疾病严重度评分高于女性;非白人种族等待名单年龄更轻。
核心结论
- 在英国和美国国家肝移植登记20年数据分析中,PSC已成为自身免疫性肝病中肝移植的主要指征。
- PBC等待名单人数及PBC女性与男性比例均下降近50%,可能由于熊去氧胆酸治疗增加。
- 在PBC、PSC或AIH等待名单患者中,年龄、性别、疾病严重度评分和种族在不同疾病和国家间存在差异,需要进一步研究。
研究设计与样本
- 研究收集1995年1月1日至2014年12月31日英国和美国国家登记系统中所有成人肝移植等待名单数据。
- 分析PBC患者(英国n=1434,美国n=5598)、PSC患者(英国n=1093,美国n=6820)和AIH患者(英国n=538,美国n=4949)。
- 每年名单数量按各年估计人口进行调整,使用回归分析检查趋势,比较统计学评估组间个体特征差异。
主要发现
- 整个研究期间,PBC名单数量在英国和美国分别为每百万人口每年1.2和1.0;PSC分别为0.9和1.2;AIH分别为0.5和0.8。
- 研究期间,PBC名单数量在英国和美国均下降50%;PSC和AIH名单数量变化较小且两国间不一致。
- 至2014年,PSC已成为两国自身免疫性肝病中肝移植的主要指征。
- 等待名单时中位患者年龄低于AIH和PBC报告的中位诊断年龄。
- 1995年至2014年,PBC女性与男性比例下降近50%;两国PSC男性等待名单时疾病严重度评分高于女性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The rarity of autoimmune liver disease poses challenges to epidemiology studies. However, waitlists for liver transplantation can be used to study patients with end-stage liver diseases. We used these waitlists to assess trends in numbers and demographics of patients awaiting liver transplant for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), or autoimmune hepatitis (AIH). METHODS: We collected data from UK and US national registries for all adults on liver transplant waitlists, from January 1, 1995, through December 31, 2014. We analyzed data from patients with PBC (n = 1434 in the United Kingdom and n = 5598 in the United States), PSC (n = 1093 in the United Kingdom and n = 6820 in the United States), and AIH (n = 538 in the United Kingdom and n = 4949 in the United States). Numbers of listings per year were adjusted to the estimated populations during each year. Regression analyses were used to examine trends and comparative statistics were used to evaluate differences in individual characteristics among groups. RESULTS: Over the total study period, listings for PBC were 1.2 and 1.0 per million population per year in the United Kingdom and United States, respectively; for PSC, 0.9 and 1.2 per million population per year; and for AIH, 0.5 and 0.8 per million population per year. Over the period studied, numbers of listings for PBC decreased by 50% in both countries; changes in numbers of listings for PSC and AIH were smaller and not consistent between countries. By 2014, PSC had become the leading indication for liver transplantation among patients with autoimmune liver diseases in both countries. Median patient ages at time of listing were lower than those reported as median age of diagnosis for AIH and PBC. The ratio of women:men with PBC decreased by almost 50% from 1995 through 2014. Men with PSC were placed on the waitlist with higher disease severity scores than women in both countries. Among patients with PBC, those of black race were under-represented on waitlists from both countries. Among patients with PSC, Hispanics were under-represented on waitlists in the United States. Patients of non-white races were placed on waitlists at younger ages for all diseases; age differences in waitlist placement varied by up to 10 years, depending on race, among patients with PBC. CONCLUSIONS: In an analysis of data collected from UK and US national liver transplant registries over 20 years, we found that PSC has become the leading indication for liver transplantation among patients with autoimmune liver diseases. Numbers of patients with PBC placed on waitlists, and the ratio of women:men with PBC, each decreased by almost 50%, possibly due to increased treatment with ursodeoxycholic acid. Within groups of patients on the transplant waitlist for PBC, PSC, or AIH, we found differences in age, sex, disease severity scores, and ethnicity between diseases and countries that require further study.
引用
- Webb GJ, Rana A, Hodson J, et al. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2017. PMID: 28993258. doi:10.1016/j.cgh.2017.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。